Cedarline Health
CEDARLINE MEDICAL CENTER, SACRAMENTO
2100 Halcyon Parkway, Sacramento, CA 95816
Phone: (916) 555-0142 | NPI: 1730345829 | Tax ID: 94-2788907
Medication Administration Record (MAR) — First 48 Hours
Units: Emergency Department (04/14); Medical Intensive Care Unit (04/14 - 04/16)
Patient: Donnelly, Margaret R.
DOB / Age / Sex: 09/12/1954 / 71 / F
MRN: CLH-3358104
Account #: CMCS-202604-073318
Member ID:
Insurance: Anthem Blue Cross PPO (Group SPP-PPO-2208)
Reporting Period: 04/14/2026 19:42  to  04/16/2026 19:42
Administration Log — Chronological
Time Medication / Item Dose Route Site Administered By
04/14/2026 20:05 Blood cultures x 2 sets (peripheral)
Drawn PRIOR to first antibiotic dose.
2 sets (aerobic + anaerobic each) Peripheral venipuncture, separate sites Right antecubital; Left antecubital L. Okonkwo, RN
04/14/2026 19:50 Lactate (initial) + sepsis labs — specimen collection
Initial lactate resulted 3.8 mmol/L.
Green-top + chemistry tubes Venous draw, right AC Right AC L. Okonkwo, RN
04/14/2026 20:12 Lactated Ringer's — 30 mL/kg bolus
30 mL/kg bolus initiated; full volume completed prior to vasopressor initiation. Hemodynamic reassessment at 23:10 showed persistent MAP <65.
2040 mL (30 mL/kg x 68 kg) IV, two 18-gauge peripheral lines, pressure bag Right AC; Left forearm M. Delgado, RN
04/14/2026 20:25 Ceftriaxone 2 g IV
Administered within 1-hour target from ED arrival (19:42). Pyxis dispense verified ED Bay 2, sepsis protocol.
2 g IV, 30-minute infusion Left forearm IV M. Delgado, RN
04/14/2026 21:40 Acetaminophen 650 mg
For T 103.0 F.
650 mg PO M. Delgado, RN
04/14/2026 22:50 Lactate (repeat) — specimen collection
Repeat lactate drawn AFTER completion of 30 mL/kg crystalloid. Resulted 2.4 mmol/L.
Green-top tube Venous draw, left AC Left AC M. Delgado, RN
04/14/2026 23:10 Right internal jugular central venous catheter placement
Placed for vasopressor administration. Post-procedure imaging confirmed appropriate tip position; no pneumothorax.
Triple-lumen 16 cm Procedure — ultrasound-guided Right IJ S. Halvorsen, MD
04/14/2026 23:25 Norepinephrine bitartrate infusion
Initiated for persistent MAP <65 after completion of full 30 mL/kg LR. Titrated to peak 10 mcg/min ~01:00.
Initiated at 2 mcg/min (range ordered 2-10 mcg/min titrated to MAP >=65) IV continuous via right IJ CVC Right IJ CVC R. Castaneda, RN (ICU)
04/14/2026 23:55 MICU transfer
Transferred from ED to MICU on norepinephrine.
Transport team
04/15/2026 01:00 Norepinephrine bitartrate infusion (titration)
Peak dose; MAP achieved 78-82.
Titrated up to 10 mcg/min (peak) IV continuous via RIJ CVC RIJ CVC R. Castaneda, RN
04/15/2026 06:00 Ceftriaxone 2 g 2 g IV, 30-minute infusion RIJ CVC R. Castaneda, RN
04/15/2026 06:00 Pantoprazole 40 mg 40 mg IV push RIJ CVC R. Castaneda, RN
04/15/2026 09:30 Norepinephrine bitartrate infusion (wean)
Weaning initiated as MAP sustained >75 on reduced dose.
Weaning from 6 mcg/min, step-down q30 min as tolerated IV continuous via RIJ CVC RIJ CVC R. Castaneda, RN
04/15/2026 16:25 Norepinephrine bitartrate infusion — DISCONTINUED
Total pressor duration approximately 17 hours (23:25 on 04/14 to 16:25 on 04/15). MAP sustained >=70 off all pressors.
Off at 0 mcg/min IV RIJ CVC T. Whitman, RN
04/15/2026 08:00 Metformin 1000 mg PO BID — HELD
Held in setting of AKI / lactic acidosis risk.
Home dose held PO (held) R. Castaneda, RN
04/15/2026 08:00 Lisinopril 20 mg PO daily — HELD
Held in setting of AKI and hypotension; to resume when renal function and BP stable.
Home dose held PO (held) R. Castaneda, RN
04/15/2026 08:00 Atorvastatin 40 mg PO daily — CONTINUED
Continued.
40 mg PO R. Castaneda, RN
04/15/2026 12:00 Insulin (regular) per sliding scale
Home oral agents held; ISS while NPO/critically ill.
Per glucose-based scale SC Abdomen R. Castaneda, RN
____________________________
Charge RN — MICU — MAR verified
Printed: 04/19/2026 09:05
____________________________
Attending: David Okafor, MD — Internal Medicine/Hospitalist — NPI 1538220017
Signed electronically: 04/19/2026 09:30
CONFIDENTIAL: This document contains protected health information. Unauthorized disclosure is prohibited by federal law (HIPAA).